These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27560106)

  • 1. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.
    Negoro E; Radivoyevitch T; Polprasert C; Adema V; Hosono N; Makishima H; Przychodzen B; Hirsch C; Clemente MJ; Nazha A; Santini V; McGraw KL; List AF; Sole F; Sekeres MA; Maciejewski JP
    Leukemia; 2016 Dec; 30(12):2405-2409. PubMed ID: 27560106
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).
    Mossner M; Jann JC; Nowak D; Platzbecker U; Giagounidis A; Götze K; Letsch A; Haase D; Shirneshan K; Braulke F; Schlenk RF; Haferlach T; Schafhausen P; Bug G; Lübbert M; Ganser A; Büsche G; Schuler E; Nowak V; Pressler J; Obländer J; Fey S; Müller N; Lauinger-Lörsch E; Metzgeroth G; Weiß C; Hofmann WK; Germing U; Nolte F
    Leukemia; 2016 Sep; 30(9):1956-9. PubMed ID: 27133825
    [No Abstract]   [Full Text] [Related]  

  • 3. Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).
    Schuler E; Giagounidis A; Haase D; Shirneshan K; Büsche G; Platzbecker U; Nolte F; Götze K; Schlenk RF; Ganser A; Letsch A; Braulke F; Lübbert M; Bug G; Schafhausen P; Bacher U; Gattermann N; Wulfert M; Haas R; Germing U
    Leukemia; 2016 Jul; 30(7):1580-2. PubMed ID: 26668126
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).
    Xiong B; Liu X; Zou P; Fan L; Chen W; Li W; Liu L
    Leuk Res; 2010 Jul; 34(7):e169-72. PubMed ID: 20122730
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.
    Mallo M; Del Rey M; Ibáñez M; Calasanz MJ; Arenillas L; Larráyoz MJ; Pedro C; Jerez A; Maciejewski J; Costa D; Nomdedeu M; Diez-Campelo M; Lumbreras E; González-Martínez T; Marugán I; Such E; Cervera J; Cigudosa JC; Alvarez S; Florensa L; Hernández JM; Solé F
    Br J Haematol; 2013 Jul; 162(1):74-86. PubMed ID: 23614682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring.
    Oelschlaegel U; Westers TM; Mohr B; Kramer M; Parmentier S; Sockel K; Thiede C; Bornhäuser M; Ehninger G; van de Loosdrecht AA; Platzbecker U
    Haematologica; 2015 Mar; 100(3):e93-6. PubMed ID: 25425689
    [No Abstract]   [Full Text] [Related]  

  • 7. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.
    Leitch HA; Buckstein R; Shamy A; Storring JM
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):162-92. PubMed ID: 22901762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).
    Butrym A; Lech-Maranda E; Patkowska E; Kumiega B; Bieniaszewska M; Mital A; Madry K; Torosian T; Wichary R; Rybka J; Warzocha K; Mazur G
    BMC Cancer; 2015 Jul; 15():508. PubMed ID: 26152663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide in myelodysplastic syndromes.
    List AF
    Clin Adv Hematol Oncol; 2008 Apr; 6(4):271-2, 311. PubMed ID: 18496493
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
    Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.
    Mesa RA; Tefferi A; Li CY; Steensma DP
    Leukemia; 2006 Nov; 20(11):2063-4. PubMed ID: 16990762
    [No Abstract]   [Full Text] [Related]  

  • 12. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
    Gaballa MR; Besa EC
    Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
    Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A
    Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remitting activity of lenalidomide in treatment-induced myelodysplastic syndrome.
    Melchert M; Williams C; List A
    Leukemia; 2007 Jul; 21(7):1576-8. PubMed ID: 17392815
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA).
    Cerchione C; Catalano L; Cerciello G; Avilia S; Picardi M; Risitano AM; Pisano I; Alfinito F; Pane F
    Ann Hematol; 2015 Mar; 94(3):531-4. PubMed ID: 25135452
    [No Abstract]   [Full Text] [Related]  

  • 16. Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment.
    Krejčík Z; Beličková M; Hruštincová A; Kléma J; Zemanová Z; Michalová K; Čermák J; Jonášová A; Dostálová Merkerová M
    Cancer Genet; 2015 Apr; 208(4):156-61. PubMed ID: 25883014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
    Nomdedeu M; Maffioli M; Calvo X; Martínez-Trillos A; Baumann T; Díaz-Beyá M; Aguilar JL; Rozman M; Costa D; Esteve J; Cervantes F; Colomer D; Nomdedeu B
    Leuk Res; 2011 Sep; 35(9):1276-8. PubMed ID: 21764129
    [No Abstract]   [Full Text] [Related]  

  • 18. Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.
    Cannella L; Latagliata R; Breccia M; Carmosino I; Loglisci G; Volpicelli P; Ferretti A; Santopietro M; Vozella F; Girmenia C; Cuzzola M; Oliva EN; Alimena G
    Ann Hematol; 2012 Feb; 91(2):309-10. PubMed ID: 21625998
    [No Abstract]   [Full Text] [Related]  

  • 19. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
    Heise C; Carter T; Schafer P; Chopra R
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.